Ultrasound Scans of Babies' Livers in Pregnancies with Type 1 Diabetes
Compares fetal liver ultrasound images in pregnant people with type 1 diabetes and healthy controls.
Plain-language title generated from the registry record
Registry title: Noninvasive Evaluation of Fetal Hyperinsulinemia With Ultrasound Radiomics
Key facts
- Where
- Turku, FinlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06343974, who can take part
Where in Finland
- Turku University HospitalTurku, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Turku University Hospital
- Trial code
- NCT06343974
- Record updated
- 28 November 2025
- Original description
The goal of this observational study is to compare fetal liver ultrasound radiomics between pregnancies complicated by type 1 diabetes and healthy controls.Read full original descriptionShow less
Noninvasive Evaluation of Fetal Hyperinsulinemia With Ultrasound Radiomics
The goal of this observational study is to compare fetal liver ultrasound radiomics between pregnancies complicated by type 1 diabetes and healthy controls.
The main questions it aims to answer are:
* Are fetal liver ultrasound radiomic features reproducible? * Does fetal liver ultrasound radiomics differ between pregnancies complicated by type 1 diabetes and healthy controls?
Participants will undergo ultrasound examination to collect ultrasound data for the analyses.
Inclusion: Age between 18-45 years; Capable to give an informed consent; Singleton pregnancy; Planning to deliver in Turku University Hospital; Maternal BMI < 40; Gestational age should be confirmed by first trimester ultrasound; Normal oral glucose tolerance test (OGTT) at 24-28 gestational weeks in controls.
Exclusion: Verified fetal infection (e.g. cytomegalovirus, toxoplasma, hepatitis B and C), excluding bacterial infection due to intrapartum chorioamnionitis; Placenta accreta spectrum disorder; Major maternal medical condition requiring systemic pharmacological treatment, other than non-severe hypertension, hypothyroidism, asthma, mild psychiatric disorders, etc; Major fetal chromosomal, genetic, or structural anomaly; Fetal growth restriction, or birth weight < 10th centile; Birth weight > 90th centile or polyhydramnios in the controls; Non-reassuring fetal status requiring immediate treatment, or intrauterine fetal demise; Alcohol or tobacco use, or substance abuse in pregnancy.